Medtech

3 Boomerang Capital I, L.P. is a healthcare-focused private equity fund targeting the lower middle market, managed by 3 Boomerang Capital (3BC), a Greenwich, Connecticut–based firm founded in 2023 by Adam Dolder and Adam Elberg. Both founders bring prior careers as both healthcare investors and healthcare entrepreneurs — a dual background the firm describes as fundamental to its differentiated approach. 3BC focuses exclusively on founder-led businesses in the healthcare sector, providing not only capital but operational guidance drawn from firsthand experience scaling and managing healthcare enterprises. The firm operates with an eleven-person team structured to provide hands-on engagement with portfolio companies. 3 Boomerang Capital I targets four sub-sectors within healthcare: BioPharma outsourcing (contract research, manufacturing, and laboratory services), medical device and diagnostic manufacturing, information technology and tech-enabled services for healthcare, and alternate site care (outpatient, home health, and specialty clinic settings). The fund targets lower middle market businesses — typically generating $10M–$100M in revenue — where management depth, succession planning, and operational systems can benefit from private equity partnership. Geographic focus spans North America and select Western European markets with established healthcare infrastructure. Fund I surpassed its $350 million target, closing above $375 million of total commitments from a diversified LP base including leading endowments, foundations, pension funds, insurance companies, fund-of-funds, and family offices, in addition to 3BC professionals. The final close was announced on February 6, 2024. Initial portfolio activity includes a growth recapitalization of Professional Physical Therapy (ProPT), described as the largest outpatient physical therapy business in the Northeastern United States. The successful above-target close on its inaugural fund validates the founding team's thesis that founder-aligned, healthcare-specialist private equity is a durable and differentiated strategy in the lower middle market.

AAIC Africa Healthcare Fund (AHF No. 1) is a $47 million impact-oriented venture capital fund focused exclusively on healthcare and medical technology startups across sub-Saharan Africa and North Africa, managed by AAIC Investment Pte. Ltd. (Asia Africa Investment & Consulting), headquartered in Singapore. AHF1 was established in 2017 as the first Japanese-affiliated venture capital fund to operate from Kenya, marking a landmark in Japanese private capital engagement with the African startup ecosystem. The fund was inspired by an assessment of the acute shortage of healthcare infrastructure across Africa and the concurrent emergence of mobile-first health technology startups capable of leapfrogging traditional delivery systems. The advisory committee includes Mr. Yoshiyuki Sato, with 50 years of Africa business experience, and Dr. Amit N. Thakker, Chairman of the Africa Healthcare Federation. AHF1 deploys tickets between $100,000 and $5 million per company, targeting seed through Series B stages across four primary African markets: Kenya, Nigeria, South Africa, and Egypt — countries representing the largest and most developed startup ecosystems on the continent. The investment mandate covers the full healthcare stack: primary care and hospital services, diagnostics, digital health and telemedicine, pharmaceutical distribution, medical devices, and healthcare-adjacent fintech applications including healthcare payment infrastructure. AAIC operates from offices in Nairobi, Lagos, and Johannesburg, enabling close portfolio engagement and deal sourcing across the region. AHF1 invested in 30 companies over its deployment cycle and has produced notable portfolio outcomes. Chipper Cash, a fintech-adjacent portfolio company, achieved unicorn status in 2021 following its $250 million Series C funding round led by Decacorn Capital. The fund's success catalyzed AAIC's expansion into a second vehicle, the Africa Innovation and Healthcare Fund (AHF2), which broadened the mandate beyond healthcare to include broader innovation sectors. AHF1 remains a pioneering example of Japanese institutional capital accessing the African venture ecosystem through a specialized healthcare and impact-aligned strategy.

The Africa Innovation and Healthcare Fund 1 (AHF-1) is a venture capital and impact fund managed by AAIC Investment, a Japan-based investment manager dedicated to advancing healthcare and innovation across the African continent. Launched in 2017 as Japan's first fund with an exclusive focus on the African healthcare sector, AHF-1 represents a pioneering effort to channel institutional capital from Japanese financial institutions and corporations into high-growth, mission-driven businesses across Sub-Saharan Africa. AHF-1 targets early- to late-stage companies operating across the full spectrum of healthcare and adjacent verticals, including clinical care, medical services, digital health, health technology, pharmaceutical distribution, insurance, diagnostics, and health-enabling infrastructure such as fintech and mobility. The fund takes equity positions and provides hands-on operational and strategic support to portfolio companies through AAIC's deep local networks in Kenya, Nigeria, Egypt, Rwanda, and other key African markets. The investment thesis centers on the belief that healthcare companies in Africa can achieve strong financial returns while addressing acute social challenges in underserved markets. AHF-1 reached a final close at USD 47 million and deployed capital across more than 30 startups and established companies, establishing AAIC Investment as one of the leading Japan-Africa impact investors in the private markets space. The fund's success laid the foundation for the Africa Innovation and Healthcare Fund 2 (AHF-2), launched in 2022 with a USD 150 million target, continuing to scale the manager's pan-African healthcare investment franchise. AAIC Holdings Pte. Ltd., headquartered in Singapore, serves as the parent organization with regional operations across Africa and Asia.

Ascenta Capital Fund I is the inaugural $325 million venture capital vehicle raised by Ascenta Capital, a Boston-based biotech investment firm co-founded in 2023 by Evan Rachlin, MD, and Lorence Kim, MD—both former senior executives at Moderna. The fund was established to back development-stage biotechnology companies with differentiated multi-medicine platforms, targeting transformative therapies at the frontier of human medicine. The founding team collectively brings deep expertise from over 30 approved medicines across oncology, rare disease, immunology, and infectious disease. Ascenta Capital Fund I achieved its final close of $325 million in October 2025, having attracted capital from leading institutional investors drawn to the founders' operator background and clinical-stage differentiation thesis. The fund's investment strategy concentrates on early human trials—typically Series A and crossover rounds—in biotech companies that possess broad, multi-medicine pipelines rather than single-asset bets. Target companies must demonstrate a platform capable of generating multiple therapeutic programs across related disease areas, allowing Ascenta to compound value through portfolio adjacencies. Geographic focus is primarily the United States, where the biotech innovation ecosystem provides the deepest pipeline of pre-clinical and early-clinical candidates. The eight-person investment team applies both clinical development judgment and capital market expertise to portfolio construction, emphasizing drug discovery quality and regulatory path clarity as primary diligence filters. Early portfolio investments include Angitia Biopharmaceuticals, TRIANA Biomedicines, and Iambic Therapeutics, all reflecting the fund's thesis around platform-driven drug discovery. Ascenta Capital Fund I is supported by a broader 14-person team that includes three executive advisors, lending additional therapeutic-area depth for each investment thesis. The fund operates out of Ascenta Capital's primary office and represents the first chapter of what the founders envision as a series of vehicles dedicated to backing the next generation of multi-medicine biotechnology companies.

Atlas Venture Fund XIV is a $450 million early-stage venture capital fund closed in December 2024 — the fourteenth in Atlas Venture's flagship biotech series and the firm's second oversubscribed fundraise in a row. Raised at the same size as its predecessor Fund XIII (2022), the consistent fund size reflects Atlas's deliberate 'VC math problem' thesis: early-stage biotech returns degrade with fund size, and a disciplined cap is a competitive advantage. Atlas Venture is based in Cambridge, Massachusetts, and manages approximately $3 billion across all vehicles. Fund XIV employs Atlas's distinctive seed-led venture creation model, in which the firm co-founds or incubates portfolio companies alongside scientific founders rather than receiving outside pitches. The fund invests at the seed and Series A stages across all major disease areas, treatment modalities, and business models — tracking breakthrough biology wherever it emerges from academic institutions globally, then building companies around it from Cambridge. Investing partners are Kevin Bitterman, Bruce Booth, Michael Gladstone, David Grayzel, and Jason Rhodes. The fund operates alongside Atlas Venture Opportunity Fund III ($400M, closed September 2025), which provides follow-on capital to maturing portfolio companies. Since Fund XIII closed in March 2022, Atlas generated a string of exits: four acquisitions (Nimbus/Tyk2 program, Versanis Bio, Aiolos Bio, Mariana Oncology), four IPOs (Disc Medicine, Korro Bio, Q32 Bio, Third Harmonic Bio), and an FDA approval (Day One Biopharmaceuticals Ojemda for pediatric low-grade glioma). Across its lifetime, Atlas has launched 92 biotech startups, achieved 43 IPOs, completed 39 M&A exits, and contributed to the development of over 30 approved medicines.

Columbus Innvierte Life Science I is the debut venture capital fund managed by Columbus Venture Partners, a Valencia, Spain-based life sciences investor founded in 2016 by Javier García and Damià Tormo. The fund was registered with the Spanish securities regulator CNMV (registration no. 190) and launched in April 2016 as part of Spain's Innvierte programme, a public-private co-investment initiative supporting early-stage innovation. The fund raised EUR 42 million and had an investment period running from 2016 to 2018, making seed and Series A investments in deep biotech and advanced therapy companies, primarily in Spain. The fund's strategy combined scientific expertise in therapeutic development with an industrial vision, targeting companies working on cell and gene therapies, AAV vector manufacturing, and other disruptive life sciences platforms. Columbus Venture Partners brought a distinctive approach of investing in both product development and the manufacturing infrastructure required to scale these technologies, thereby shortening time to exit. The geographic focus was Spain with international reach, co-investing alongside specialist international and corporate venture funds. The fund built a portfolio of eight investments and has since generated exceptional returns through landmark exits. Viralgen Vector Core was sold to Bayer in 2020 in a transaction valued at approximately EUR 4 billion. Vivet Therapeutics was acquired by Pfizer for an upfront and option value of EUR 560 million. Aura Biosciences completed a NASDAQ IPO in 2021. Columbus Venture Partners now manages over EUR 400 million across four successive funds, establishing itself as one of Spain's leading life sciences venture capital franchises.

Deerfield Healthcare Innovations Fund III is the third installment in Deerfield Management's series of venture capital funds dedicated to advancing healthcare. Launched in May 2025, the fund has secured over $600 million in commitments, aiming to invest in promising therapeutics, improvements to healthcare delivery, and paradigm-shifting technologies, including machine learning and artificial intelligence. The fund's strategy leverages Deerfield's collaborations with 29 leading research institutions and nine industry partners. Through its in-house ecosystem, including specialized teams like Deerfield Discovery and Development (3DC) and Deerfield Intelligence, the firm identifies and advances innovative products, services, and technologies. These efforts are often in partnership with Deerfield-founded entities such as Deerfield Catalyst and Genscience. Operating from its twelve-story healthcare innovation campus, Cure, in New York City, Deerfield provides state-of-the-art research laboratories and convening spaces to support health innovators. Consistent with its long-standing practice, a portion of the profits from Healthcare Innovations Fund III not allocated to the fund's limited partners will be donated to the Deerfield Foundation, a not-for-profit organization focused on improving the health of children worldwide.

The fund is the fourth flagship vehicle from GHO Capital, leveraging its deep specialization in healthcare to back companies delivering better, faster and more accessible care. With its final close at over €2.5 billion, the vehicle is positioned to scale high‑growth businesses across services, medtech, diagnostics and health‑tech platforms. GHO Capital IV focuses on companies where strong management, operational improvement and international expansion can unlock significant value. The fund partners with leadership teams in niche but growing healthcare subsectors and applies the firm’s sector insight, global network and operational resources to drive transformation. The strategy targets enterprises that serve pharmaceutical, biotechnology and medical device customers — such as CDMOs, contract services, outsourcing platforms, diagnostics manufacturers and digital health enablers — where structural tailwinds and under‑penetrated markets offer runway for growth. Geographically, the fund emphasises Europe and North America but retains flexibility to leverage cross‑border dynamics, enabling portfolio companies to scale internationally. Through disciplined buy‑outs, add‑on consolidation and operational acceleration, GHO Capital IV aims to d

Mérieux Innovation 2 (MI2) is the second-generation venture capital fund managed by Mérieux Equity Partners, focused on advancing innovation in the healthcare sector. Building on the success of its predecessor, MI2 is designed to support early-stage companies with high-impact solutions across diagnostics, medical devices, and pharmaceutical services. The fund targets platform-based business models with validated proof of concept, offering scalability and long-term growth potential. MI2 combines capital investment with strategic guidance and access to a robust healthcare ecosystem, helping portfolio companies accelerate development and go-to-market strategies. MI2 has received the prestigious Tibi label, highlighting its commitment to driving technological innovation within France and the broader European healthcare landscape. It aims to generate strong returns while contributing meaningfully to patient care and clinical outcomes. The fund’s first investment is a €6 million commitment to DeepUll, a Spanish diagnostics company developing rapid sepsis detection technology. This aligns with MI2’s goal of supporting transformative platforms that address critical medical needs.